
No results matched your search
Canaccord Genuity analyst Max Masucci maintained a Buy rating on Genmark Diagnostics on Thursday, setting a price target of $24, which is approximately 24.42% above the present share price of $19.29.
Masucci expects Genmark Diagnostics to post earnings per share (EPS) of -$0.05 for the first quarter of 2021.
The current consensus among 3 TipRanks analysts is for a Moderate Buy rating of shares in GenMark (NASDAQ:GNMK), with an average price target of $23.
The analysts price targets range from a high of $24 to a low of $22.
In its latest earnings report, released on 09/30/2020, the company reported a quarterly revenue of $42.65 million and a net profit of -$1.27 million. The company's market cap is $1.48 billion.
According to TipRanks.com, Canaccord Genuity analyst Max Masucci is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 90.7% and a 85.88% success rate.
GenMark Diagnostics, Inc. is a molecular diagnostics company, which engages in the provision of multiplex molecular diagnostic solutions. Its products include ePlex and XT-8. The company was founded by Jon Faiz Kayyemin 1993 and is headquartered in Carlsbad, CA.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.